Clinical trials: Sepsis Septic Shock
Severe Sepsis, Septic Shock
Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock
Early intervention in the treatment of septic shock, including early goal-directed therapy (EGDT) in the first 6 hours of disease presentation, has been shown to significantly decrease mortality.
- Trial name
- MiCHO (NCT00535821)
- Testing
- Esophageal Doppler monitoring - CardioQ, Deltex Inc, Central line with CVP and continuous ScvO2 monitoring
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Loma Linda University
Septic Shock
Acetyl-L-Carnitine in the Treatment of Septic Shock
This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.
- Trial name
- ALC (NCT00592488)
- Testing
- Acetyl-L-Carnitine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt University
Septic Shock
HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
This study will be conducted as a single-center, prospective, open-label, randomized trial that will evaluate adult patients admitted with septic shock to the medical critical care unit (MCC).
- Trial name
- NCT03710187
- Testing
- Hydrocortisone
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Tennessee Medical Center
New Onset Atrial Fibrillation, Severe Sepsis
Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock
Purpose/Objectives: Severe sepsis and septic shock are a common cause of new onset atrial fibrillation (NOAF) in the intensive care unit. Development of NOAF in this setting can prolong length of stay and increase mortality.
- Conditions
- New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock
- Trial name
- NCT02668432
- Testing
- Amiodarone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Sepsis, Severe Sepsis
Protocolized Care for Early Septic Shock
The ProCESS study is large, 5-year, multicenter study of alternative resuscitation strategies for septic shock. The study hypothesizes that there are "golden hours" in the initial management of septic shock where prompt…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- ProCESS (NCT00510835)
- Testing
- Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
- Where
- 31 sites in United States
- Volunteers
- 1,351 people
- Sponsor
- University of Pittsburgh
Septic Shock, Sepsis
Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)
Sepsis is a common syndrome resulting from a dysregulated response to infection. The timing of antibiotic initiation is an important determinant of outcomes for patients presenting to the emergency department with sepsis.
- Trial name
- NCT03226366
- Testing
- Immediate evaluation by multidisciplinary team
- Where
- 4 sites in United States
- Volunteers
- 3,230 people
- Sponsor
- Intermountain Health Care, Inc.
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals
Sepsis
Immunomodulatory Properties of Ketamine in Sepsis
The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock.
- Trial name
- NCT01089361
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Beth Israel Deaconess Medical Center
Severe Sepsis
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
- Trial name
- NCT02960854
- Testing
- Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Multiple Organ Failure, Septic Shock
Early Metabolic Resuscitation for Septic Shock
This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock.
- Conditions
- Multiple Organ Failure, Septic Shock, Severe Sepsis
- Trial name
- NCT03895853
- Testing
- Best Practice, early metabolic resuscitation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Shock, Septic
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients…
- Trial name
- NCT03158948
- Testing
- Nangibotide 0.3 mg/kg, Nangibotide 1 mg/kg, Nangibotide 3 mg/kg
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Inotrem
Septic Shock
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
The purpose of this trial was to examine the safety and tolerability, pharmacokinetics of FE 202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood vessel) leakage.
- Trial name
- NCT01000649
- Testing
- FE 202158 1.25, FE 202158 2.5, FE 202158 3.75
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Ferring Pharmaceuticals
Septic Shock, Acute Kidney Injury
Renin and Renal Biomarker Response to Angiotensin II
Septic shock continues to exert a large economic burden around the world. Several developments have occurred that lead to the current study.
- Trial name
- NCT04558359
- Testing
- Standard of Care, Angiotensin II
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alexander Flannery
Sepsis, Septic Shock
Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial
In this study, we aim to determine whether the combination of Ascorbic Acid (Vitamin C), Thiamine (Vitamin B1), and Corticosteroids improves the trajectory of organ failure and reduces mortality in patients with sepsis and septic…
- Conditions
- Sepsis, Septic Shock, Metabolic Disturbance
- Trial name
- NCT03389555
- Testing
- vitamin C, vitamin B1, hydrocortisone, Normal saline
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- Beth Israel Deaconess Medical Center
Toxic Shock Syndrome, Vaccination; Sepsis
rTSST-1 Variant Vaccine Phase 1 First-in-man Trail
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- rTSST-1 (NCT02340338)
- Testing
- rTSST-1 Variant Candidate Vaccine
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Septic Shock
Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia
This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion.
- Trial name
- ECASSS-R (NCT02841241)
- Testing
- Esmolol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Intermountain Health Care, Inc.
Sepsis
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients…
- Trial name
- NCT00604214
- Testing
- Drotrecogin alfa (activated)
- Where
- 150 sites in United States, Australia and 16 more
- Volunteers
- 1,696 people
- Sponsor
- Eli Lilly and Company
Sepsis, Septic Shock
Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Investigators propose to investigate the use of IV vitamins B1 and C in a randomized, double-blinded, prospective trial to determine if these medications decrease mortality rates in patients with severe sepsis or septic shock.
- Trial name
- NCT03592277
- Testing
- Vitamin C, Vitamin B1
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Trinity Health Of New England
Septic Shock, Sepsis
Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients
Septic shock is a condition that is marked by severe infection causing hypotension requiring vasopressors to maintain adequate perfusion to vital organs.
- Conditions
- Septic Shock, Sepsis, Shock, Tachycardia
- Trial name
- NCT02203630
- Testing
- Phenylephrine, Norepinephrine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Vanderbilt University Medical Center